Figure 1. Treg cell depletion unleashes IFNγ-producing γδ T cell responses. (A) Schematic representation of the experimental approach. 1 × 10⁶ of E0771 breast cancer cells were inoculated subcutaneously in the mammary fat pad of Foxp3-DTR mice. More about this image found in Treg cell depletion unleashes IFNγ-producing γδ T cell responses. (A) Sche...

Figure 2. IFNγ-biased Vγ1 ⁺ γδ T cells are anti-tumor effectors of Treg depletion therapy. ( A ) Schematic representation of the experimental approach. 1 × 10⁶ of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR More about this image found in IFNγ-biased Vγ1 ⁺ γδ T cells are anti-tumor effectors of Treg ...

Figure 3. Treg cells suppress IFNγ-producing γδ T cells by draining IL-2 . (A) Quantification and representative density plots of CD25 and CD122 expression by IFNγ⁺ γδ T cells and Treg cells in spleen, dLN, and tumors of DTx- (only IFNγ⁺ γδ T More about this image found in Treg cells suppress IFNγ-producing γδ T cells by draining IL-2 . (A) Quan...

Figure 4. IL-2 neutralization in the absence of Treg cells limits anti-tumor γδ T cell responses and impairs tumor control. (A) Schematic representation of the experimental approach. 1 × 10⁶ of E0771 breast cancer cells were inoculated in the More about this image found in IL-2 neutralization in the absence of Treg cells limits anti-tumor γδ T cel...

Figure 5. IL-2Rβ γ_c agonism promotes anti-tumor murine γδ T cell responses and tumor control. (A) Schematic representation of the experimental approach. 1 × 10⁶ of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR More about this image found in IL-2Rβ γ_c agonism promotes anti-tumor murine γδ T cell responses...

Figure 6. IL-2Rβγ _c agonism circumvents human Treg suppression and enhances therapeutic γδ T cell responses. (A) Quantification and representative density plots of proliferating sorted Vδ2⁺ T cells (measured by dilution of CellTrace Violet More about this image found in IL-2Rβγ _c agonism circumvents human Treg suppression and enhan...

Figure 1. Feeder-based expansion supports NK cell proliferation and nonviral HDR knock-in. (A) Relationship between cell cycle and HDR. (B) Schematic of the CTV assay. Irradiated feeder cells are 100-Gy γ-irradiated mbIL21-41BBL K562 cells. More about this image found in Feeder-based expansion supports NK cell proliferation and nonviral HDR knoc...

Figure 2. Development of a highly efficient nonviral knock-in platform for NK cell engineering. (A) Overview of platform development workflow. (B) HDR-mediated knock-in of mNeonGreen at the CD96 locus. (C) Representative flow cytometry plot More about this image found in Development of a highly efficient nonviral knock-in platform for NK cell en...

Figure 3. Robust nonviral knock-in enables fluorescent tagging of endogenous proteins. (A) Schematics of N and C terminus endogenous protein tagging strategies. (B) Overview of protein tagging validation. LHA, left homology arm; RHA, right More about this image found in Robust nonviral knock-in enables fluorescent tagging of endogenous proteins...

Figure 4. Tunable transgene expression via integration at housekeeping gene loci. (A and B) Schematic of (A) first exon and (B) last exon (with stop codon) targeting strategy. (C) HDR knock-in efficiency and MFI of P2A-mNeonGreen at different More about this image found in Tunable transgene expression via integration at housekeeping gene loci. (A ...

Figure 5. Optimized conditions and template design support plasmid-based nonviral knock-in of therapeutically relevant transgenes. (A) Workflow of combined validation of optimized strategies with different pulse programs. (B) Relative HDR More about this image found in Optimized conditions and template design support plasmid-based nonviral kno...

Figure 6. One-step multiplex therapeutic engineering of NK cells via nonviral knock-in at a housekeeping gene locus. (A) Nonviral knock-in therapeutically relevant synthetic transgene payloads at the GAPDH locus using the pUCmu vector-based More about this image found in One-step multiplex therapeutic engineering of NK cells via nonviral knock-i...

Figure 7. CISH-converted OR-gated CAR with sIL15 augments NK cell function. (A) Knock-in of anti-CD22/CD19 CAR (CAR.22.19) and sIL15 at the CISH locus. (B) Representative flow cytometry plots of CISH-converted armored anti-CD22/CD19 CAR-NK More about this image found in CISH-converted OR-gated CAR with sIL15 augments NK cell fu...

Figure 8. Hypoxia-restricted IL-12 secretion via PFKFB4 transcriptional control. (A) Schematic of IL-12 and tNGFR reporter knock-in at the PFKFB4 locus. tNGFR, truncated nerve growth factor receptor. (B) Expression of IL-12 and tNGFR reporter More about this image found in Hypoxia-restricted IL-12 secretion via PFKFB4 transcriptio...

Figure 9. GMP-compatible nonviral clinical manufacturing of CAR-NK cells. (A) Workflow of GMP-compatible CAR-NK cell production using nonviral genome editing. (B) Targeted integration of CAR.22.19 and sIL15 into the CISH locus using SpyFi Cas9 More about this image found in GMP-compatible nonviral clinical manufacturing of CAR-NK cells. (A) Workfl...